Kana Lessig Stemsoft Software -

The field of cellular therapy is moving at breakneck speed. CAR-T, IEC, and other advanced therapy medicinal products (ATMPs) are revolutionizing patient care, transforming how we treat cancer and other diseases. Yet, with this incredible innovation comes a complex reality: managing the data of human cells as a raw material requires unprecedented precision.

STEMSOFT is a well-established division of , led by President and CEO Rob Fuller , and was founded in 1993 by Dr. Allen Eaves . Kana Lessig Stemsoft Software

As the industry moves from bench to bedside, the bottleneck often isn't the science—it’s the documentation. The Challenge of Modern Cellular Therapies The field of cellular therapy is moving at breakneck speed

By utilizing electronic batch process records (eBPR), facilities can reduce the burden of documentation, allowing researchers and clinicians to focus on producing perfect products, not just perfect paperwork. Partnering for the Long Term STEMSOFT is a well-established division of , led

Manufacturing and administering advanced therapies requires complete, accurate, and detailed records. Whether you are a cord blood bank, a public marrow transplant center, or a commercial cell therapy manufacturer, the regulatory landscape is constantly evolving, requiring strict adherence to FACT/JACIE, AABB, cGMP, and cGTP standards.